Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.
The tolerance and antitumor activity of Lonidamine administered alone and in combination with other anticancer agents were studied. Myalgia was the most frequent side effect; there were no changes in the hematological parameters attributable to Lonidamine administration. 1 partial response out of the 16 patients treated with Lonidamine alone was observed.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects; D011720:Pyrazoles / Q000627:therapeutic use*; D011897:Random Allocation
D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine